 This is a prospective, multi-center, randomized, placebo-controlled trial in subjects with histological evidence of 33 hepatic steatosis or nonalcoholic steatohepatitis NASH and chronic hepatitis C. Patients who have not been previously treated for hepatitis C treatment naive will be enrolled. 